Claims for Patent: 9,650,684

Summary for Patent: 9,650,684

Title:	Methods of identifying and using general or alternative splicing inhibitors
Abstract:	The present invention is based on the discovery of a cell-based system to identify novel modulators of splicing or splicing dependent processes. The cell-based system of the present invention utilizes a fast and highly sensitive reporter, that responds to defects in the splicing machinery itself and is sensitive to changes in the signals that regulate splicing dependent processes such as those that modulate the EJC, splicing-dependent export, localization or translation efficiency. The present invention further uses the cell-based screen to identify several small molecules that modulate both constitutive and alternative splicing. Accordingly, the present invention includes general or alternative splicing inhibitors identified using the assay described herein. The present invention also provides methods of treating a subject having a condition associated with aberrant target RNA expression. The present invention further details a kit that may be directed to specifically detecting a general or alternative splicing inhibitor of the invention.
Inventor(s):	Dreyfuss; Gideon (Wynnewood, PA), Younis; Ihab (Philadelphia, PA), Wan; Lili (Westfield, NJ)
Assignee:	The Trustees of the University of Pennsylvania (Philadelphia, PA)
Application Number:	13/321,849
Patent Claims:	1. A method of identifying a candidate general or alternative splicing inhibitor of RNA splicing comprising a two step assay, said method comprising the steps of: a) a first screening step comprising assessing the effect of a candidate general or alternative splicing inhibitor on expression, function, or activity of a first reporter construct expressed by a first recombinant mammalian cell by exposing said candidate general or alternative splicing inhibitor to said first recombinant cell for less than 4 hours, said first reporter construct comprising an open reading frame (ORF) interrupted by a chimeric .beta.-globin intron, wherein the chimeric .beta.-globin intron comprises multiple internal stop codons, wherein protein translated from unspliced transcripts is truncated, further wherein said first reporter construct comprises a protein and RNA destabilizing sequence and has a half-life of less than 4 hours, wherein the candidate alternative splice inhibitor is selected for a subsequent counter screen when the candidate inhibits the expression, activity, or function of the reporter protein relative to control; b) after the first screening step, a second counter-screening step comprising assessing the effect of the selected candidate inhibitor from the first screen on the expression, function, or activity of a second reporter construct expressed by a second recombinant mammalian cell by exposing the selected candidate inhibitor from the first screen to said second recombinant cell for less than 4 hours, said second reporter construct comprising an intronless ORF, further wherein said second reporter construct comprises a protein and RNA destabilizing sequence and has a half-life of less than 4 hours, wherein when the selected candidate inhibitor has a different effect on the expression, function, or activity of the intronless reporter construct of the first screening step as compared to the intron containing reporter construct, then the selected candidate compound is identified as an inhibitor of constitutive or alternative splicing. 2. The method of claim 1, wherein said first reporter construct encodes luciferase. 3. The method of claim 2, wherein said intronless reporter construct is Luc. 4. The method of claim 2, wherein said intron-containing reporter construct is Luc I.

Details for Patent 9,650,684

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2029-05-22
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2029-05-22
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2029-05-22